Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-l production in the small intestine

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 6, 2009, Pages 642-649

  Dullens, Stefan P J ^a   Mensink, Ronald P ^a   Mariman, Edwin C M ^a   Plat, Jogchum ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Apolipoprotein A l; HepG2 cells; Lipoproteins; Nuclear receptors

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; APOLIPOPROTEIN A1; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; RETINOID X RECEPTOR ALPHA; TAUROCHOLIC ACID;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPROTEIN SYNTHESIS; MODEL; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; SMALL INTESTINE; TRANSACTIVATION;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; BUTYRIC ACIDS; CACO-2 CELLS; CELL DIFFERENTIATION; DRUG EVALUATION, PRECLINICAL; HEP G2 CELLS; HUMANS; INTESTINE, SMALL; ISOXAZOLES; MODELS, BIOLOGICAL; PEROXISOME PROLIFERATORS; PHENYLUREA COMPOUNDS; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 67649757581     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328321b0c8     Document Type: Article

References (48)

1. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J 2004; 148:S14-S18.
2. Schaefer EJ, Lamorv-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PW. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-l levels in the Framingham Offspring Study. J Lipid Res 1994; 35:871-882.
3. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-l, lipoprotein A-l, and lipoprotein A-l/A-ll in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vase Biol 2002; 22:1155-1161.
4. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chern 1998; 273:5033-5036.
5. Rittershaus CW, Miller DP, Thomas U, Picard MD, Honan CM, Emmett CD, er al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vase Biol 2000; 20:2106-2112.
6. Kee P, Caiazza D, Rye KA, Barrett PH, Morehouse LA, Barter PJ. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscler Thromb Vase Biol 2006; 26:884-890.
7. Rensen PC, Havekes LM. Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport? Arterioscler Thromb Vase Biol 2006; 26:681-684.
8. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Ku'rvenhoven JA, Barter PJ, er al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 2007; 356:1620-1630.
9. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vase Biol 2007; 27:257-260.
10. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153-160.
11. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116:3090-3100.
12. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-l Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
13. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 1991; 353:265-267.
14. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, era/. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler Thromb Vase Biol 2000; 20:2267-2274.
15. Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK. Distribution of apolipoprotein A-l, C-ll, C-lll, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry 1985; 24:4450-4455.
16. Baroukh N, Lopez CE, Saleh MC, Recalde D, Vergnes L, Ostos MA, er al. Expression and secretion of human apolipoprotein A-l in the heart. FEBS Lett 2004; 557:39-44.
17. Zannis VI, Liu T, Zanni M, Kan HY, Kardassis D. Regulatory gene mutations affecting apolipoprotein gene expression: functions and regulatory behavior of known genes may guide future pharmacogenomic approaches to therapy. Clin Chem Lab Med 2003; 41:411-424.
18. Eggerman TL, Hoeg JM, Meng MS.Tombragel A, Bojanovski D, Brewer HB Jr. Differential tissue-specific expression of human apoA-l and apoA-ll. J Lipid Res 1991;32:821-828.
19. Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992; 43:625-633.
20. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, ef al. Opposite regulation of human versus mouse apolipoprotein A-l by fibrates in human apolipoprotein A-l transgenic mice. J Clin Invest 1996; 97:2408-2416.
21. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, Branellec D, ef al. Beneficial effects of fibrates on apolipoprotein A-l metabolism occur independently of any peroxisome proliferative response. Circulation 1999; 99:2445-2451.
22. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54:615-633.
23. Duez H, Lefebvre B, Poulain P.Torra IP, Percevault F, Luc G, era/. Regulation of human apoA-l by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vase Biol 2005; 25:585-591.
24. Rong R, Ramachandran S, Penumetcha M, Khan N, Parthasarathy S. Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-l production. J Lipid Res 2002; 43:557-564.
25. Giller T, Hennes U, Kempen HJ. Regulation of human apolipoprotein A-l expression in Caco-2 and HepG2 cells by all-trans and 9-cis retinoic acids. J Lipid Res 1995; 36:1021-1028.
26. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-l transcription via a negative FXR response element. J Clin Invest 2002; 109:961-971.
27. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-l promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-31018.
28. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, ef al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006; 126:2002-2009.
29. Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 2001; 276:27950-27958.
30. Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, ef al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002; 69:131-138.
31. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, ef al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003; 278:10214-10220.
32. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Cite Res 2003; 92:518-524.
33. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114:299-306.
34. Urizar NL, Livemnan AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296:1703-1706.
35. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 2004; 310:528-535.
36. Burn's TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 2005; 67:948-954.
37. Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidoi 2001; 12:181 -207.
38. Kockx M, Princen HM, Kooistra T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-l in cultured cynomolgus monkey hepatocytes - role of the peroxisome proliferator-activated receptor-alpha. Thromb Haemost 1998; 80: 942-948.
39. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
40. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-l kinetics in mixed hyperlipidemia. J Lipid Res 2004; 45:174-185.
41. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Aiheroscler Thromb 2004; 11:278-285.
42. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-l-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vase Biol 2005; 25:1193-1197.
43. Van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, etal. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007; 48:1763-1771.
44. Goldberg RB. Impact of thiazolidenediones on serum lipoprotein levels. Curr Atheroscler Rep 2006; 8:397-404.
45. Thomas C, LandrierJF, Gaillard D, Grober J, Monnot MC, Athias A, Besnard P. Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Gut 2006; 55:1321-1331.
46. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, ef al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005; 13:279-290.
47. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290:765-772.
48. Silberberg M, Morand C, Mathevon T, Besson C, Manach C, Scalbert A, Remesy C. The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. EurJNutr 2006; 45:88-96.